Using the BENEFIT and BENEFIT-EXT trials , we investigated the following : ( a ) evolution of HRQoL , assessed by the Medical Outcomes Short Form Health Survey ( SF-36 ) in the first 3 years ( baseline , 12 , 24 , and 36 months ) after kidney transplantation ; ( b ) association among kidney function ( chronic kidney disease stage ) , HRQoL , and patient-reported side effects ( Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R ; BENEFIT trial only ) ; and ( c ) impact of belatacept and cyclosporine on side effect experience and HRQoL .